Browsing by Author "Lisicic, Nikola (58288887800)"
Now showing 1 - 3 of 3
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Prognostic value of preoperative De Ritis ratio on oncological outcomes in patients with muscle-invasive bladder cancer(2024) ;Sretenovic, Milan (57222981469) ;Lisicic, Nikola (58288887800) ;Bulat, Petar (59060084900) ;Radisavcevic, Djordje (57222992997) ;Bumbasirevic, Uros (36990205400) ;Cegar, Bojan (55376116500) ;Milojevic, Isidora Grozdic (37107616900) ;Grujicic, Sandra Sipetic (56676073300)Milojevic, Bogomir (36990126400)Objective: We aimed to assess the prognostic value of De Ritis ratio on oncological outcomes in patients suffering from urothelial bladder cancer and undergoing radical cystectomy (RC). Patients and Methods: Analytical cohort comprised a single-center series of 367 patients treated between January 2015 and December 2018. Patients were classified into two groups based on De Ritis ratio (<1.3 [normal] vs. ≥1.3 [high]). Along with the Kaplan-Meier survival probability, cox proportional hazard regression models were used. Results: A total of 299 patients were included, 60.5% of them having a De Ritis ratio of <1.3% and 39.5% with a De Ritis ratio of ≥1.3. Preoperative increased De Ritis ratio was associated with age (p = 0.001), gender (p = 0.044), cancer-related death (p = 0.001), overall death (p = 0.001), and tumor stage (p = 0.001). Multivariate analysis implied that preoperative De Ritis ratio was a significant independent prognosticator of overall survival (HR 0.461; 95% CI 0.335–0.633; p < 0.001) and CSS (HR 0.454; 95% CI 0.330–0.623; p < 0.001). Only tumor stage (HR 1.953; 95% CI 1. 106–3.448; p = 0.021) was independently associated with recurrence-free survival (RFS). De Ritis ratio was not independently associated with RFS in multivariate analyses. During the follow up, a total of 198 (66.2%) patients died, including 173 (57.9%) from BC, 5-year CSS was 45.8%. Conclusions: De Ritis ratio is an independent prognostic factor of cancer specific and overall survival in patients treated with RC for urothelial BC. RC patients may benefit from the use of the De Ritis ratio as a valid predictive biomarker. © 2023 Wiley Periodicals LLC. - Some of the metrics are blocked by yourconsent settings
Publication Treatment options in stage I seminoma(2022) ;Bumbasirevic, Uros (36990205400) ;Zivkovic, Marko (57219127178) ;Petrovic, Milos (57554228900) ;Coric, Vesna (55584570400) ;Lisicic, Nikola (58288887800)Bojanic, Nebojsa (55398281100)Seminomas are most commonly diagnosed in clinical stage I (CSI). After orchiectomy, approximately 15% of patients in this stage have subclinical metastases. Adjuvant radiotherapy (ART) delivered to the retroperitoneum and ipsilateral pelvic lymph nodes has been the mainstay of treatment for many years. Although highly efficient, with long-term cancer-specific survival (CSS) rates approaching almost 100%, ART is associated with considerable long-term consequences, particularly cardiovascular toxicity and increased risk of secondary malignancies (SMN). Therefore, active surveillance (AS) and adjuvant chemotherapy (ACT) were developed as alternative treatment options. While AS prevents patient overtreatment, it is associated with strict follow-up regimens and increased radiation exposure due to repeated imaging. Due to equivalent CSS rates to ART, and lower toxicity, one course of adjuvant carboplatin presents the cornerstone of chemotherapy for CSI patients. CSS is almost 100% for patients with CSI seminoma, regardless of the chosen treatment option. Therefore, a personalized approach in treatment selection is preferred. Currently, routine radiotherapy for CSI seminoma patients is no longer recommended. Instead, it should be reserved for patients who are unfit or unwilling for AS or ACT. Identification of prognostic factors for disease relapse allowed for the development of risk-adapted treatment strategy and stratification of patients in low-risk and high-risk groups. Although risk-adapted policy needs further validation, surveillance is currently recommended in low-risk patients, while ACT is reserved for patients with a higher risk of relapse. © 2022, Tech Science Press. All rights reserved. - Some of the metrics are blocked by yourconsent settings
Publication Treatment options in stage I seminoma(2022) ;Bumbasirevic, Uros (36990205400) ;Zivkovic, Marko (57219127178) ;Petrovic, Milos (57554228900) ;Coric, Vesna (55584570400) ;Lisicic, Nikola (58288887800)Bojanic, Nebojsa (55398281100)Seminomas are most commonly diagnosed in clinical stage I (CSI). After orchiectomy, approximately 15% of patients in this stage have subclinical metastases. Adjuvant radiotherapy (ART) delivered to the retroperitoneum and ipsilateral pelvic lymph nodes has been the mainstay of treatment for many years. Although highly efficient, with long-term cancer-specific survival (CSS) rates approaching almost 100%, ART is associated with considerable long-term consequences, particularly cardiovascular toxicity and increased risk of secondary malignancies (SMN). Therefore, active surveillance (AS) and adjuvant chemotherapy (ACT) were developed as alternative treatment options. While AS prevents patient overtreatment, it is associated with strict follow-up regimens and increased radiation exposure due to repeated imaging. Due to equivalent CSS rates to ART, and lower toxicity, one course of adjuvant carboplatin presents the cornerstone of chemotherapy for CSI patients. CSS is almost 100% for patients with CSI seminoma, regardless of the chosen treatment option. Therefore, a personalized approach in treatment selection is preferred. Currently, routine radiotherapy for CSI seminoma patients is no longer recommended. Instead, it should be reserved for patients who are unfit or unwilling for AS or ACT. Identification of prognostic factors for disease relapse allowed for the development of risk-adapted treatment strategy and stratification of patients in low-risk and high-risk groups. Although risk-adapted policy needs further validation, surveillance is currently recommended in low-risk patients, while ACT is reserved for patients with a higher risk of relapse. © 2022, Tech Science Press. All rights reserved.
